|
US7563874B2
(en)
*
|
1998-08-31 |
2009-07-21 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
AU6375000A
(en)
*
|
1999-07-29 |
2001-02-19 |
Medarex, Inc. |
Human monoclonal antibodies to her2/neu
|
|
DK1276855T3
(da)
*
|
2000-04-17 |
2012-11-26 |
Dyax Corp |
Fremgangsmåde til konstruktion af visningsbiblioteker over genetiske pakker for medlemmer af en diversificeret peptidfamilie
|
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
|
MXPA02011379A
(es)
|
2000-05-19 |
2003-06-06 |
Genentech Inc |
Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
|
|
US20030119056A1
(en)
|
2000-12-18 |
2003-06-26 |
Ladner Robert Charles |
Focused libraries of genetic packages
|
|
ITRM20010408A1
(it)
*
|
2001-07-10 |
2003-01-10 |
Univ Napoli Federico Ii |
Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
|
|
EP1410806A4
(en)
*
|
2001-07-25 |
2007-07-04 |
Mitsubishi Pharma Corp |
MEDICINE FOR THE TREATMENT OF BREAST CANCER
|
|
AU2003256299A1
(en)
|
2002-07-01 |
2004-01-19 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to reg iv
|
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
US6987270B2
(en)
|
2003-05-07 |
2006-01-17 |
General Electric Company |
Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
|
|
DE602004019546D1
(de)
|
2003-08-26 |
2009-04-02 |
Smithkline Beecham Corp |
Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
|
|
KR20070003806A
(ko)
*
|
2003-11-28 |
2007-01-05 |
미트라 메디컬 아베 |
Ｅｒｂ 항원의 표적화
|
|
CN103948545B
(zh)
|
2004-05-03 |
2017-10-03 |
益普生生物制药公司 |
用于药物输送的脂质体
|
|
AU2005295072A1
(en)
|
2004-10-08 |
2006-04-20 |
Alza Corporation |
Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
|
|
KR20200058588A
(ko)
|
2005-01-21 |
2020-05-27 |
제넨테크, 인크. |
Ｈｅｒ 항체의 고정 용량 투여법
|
|
WO2007094754A2
(en)
*
|
2005-01-27 |
2007-08-23 |
The Regents Of The University Of Califordnia |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
GB0503546D0
(en)
*
|
2005-02-21 |
2005-03-30 |
Hellenic Pasteur Inst |
Antibody
|
|
MY152164A
(en)
|
2005-02-23 |
2014-08-15 |
Genentech Inc |
Extending time to disease progression or survival in cancer patients
|
|
ES2613957T3
(es)
*
|
2006-08-04 |
2017-05-29 |
Medimmune Limited |
Anticuerpos contra ERBB2
|
|
US8759087B2
(en)
|
2006-12-12 |
2014-06-24 |
Morpho Sys AG |
Internalization
|
|
KR20150039212A
(ko)
|
2007-03-02 |
2015-04-09 |
제넨테크, 인크. |
낮은 ｈｅｒ３ 발현을 기초로 한 ｈｅｒ 이량체화 억제제에 대한 반응 예측
|
|
EP2134749B1
(en)
*
|
2007-03-22 |
2013-11-06 |
The Regents of the University of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
US20090175784A1
(en)
|
2007-05-11 |
2009-07-09 |
Joshua Goldstein |
Anti-Alpha V Immunoliposome Composition, Methods, and Uses
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
SI2171090T1
(sl)
|
2007-06-08 |
2013-07-31 |
Genentech, Inc. |
Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
EP3753947A1
(en)
|
2007-09-14 |
2020-12-23 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US9873957B2
(en)
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
|
US9388510B2
(en)
|
2008-04-24 |
2016-07-12 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
US9000131B2
(en)
|
2008-07-31 |
2015-04-07 |
The Regents Of The University Of California |
Antibodies that neutralize botulinum neurotoxins
|
|
CA2779436A1
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
|
NZ594665A
(en)
|
2009-03-20 |
2013-08-30 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
WO2010136569A1
(en)
|
2009-05-29 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
|
ES2519348T3
(es)
|
2010-02-18 |
2014-11-06 |
Genentech, Inc. |
Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
|
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
|
TW201141519A
(en)
*
|
2010-03-04 |
2011-12-01 |
Symphogen As |
Anti-HER2 antibodies and compositions
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
CN103153339B
(zh)
|
2010-05-27 |
2021-05-04 |
根马布股份公司 |
针对her2表位的单克隆抗体
|
|
NZ604003A
(en)
|
2010-05-27 |
2015-04-24 |
Genmab As |
Monoclonal antibodies against her2
|
|
JP6266343B2
(ja)
|
2010-07-16 |
2018-01-24 |
アディマブ， エルエルシー |
抗体ライブラリー
|
|
WO2012047427A2
(en)
|
2010-08-31 |
2012-04-12 |
The Regents Of The University Of California |
Antibodies for botulinum neurotoxins
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
CN107252417A
(zh)
|
2010-12-06 |
2017-10-17 |
梅里麦克制药股份有限公司 |
在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药
|
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
CA2827118A1
(en)
|
2011-02-15 |
2012-08-23 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
EP2699260B1
(en)
|
2011-04-20 |
2024-11-20 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
WO2012143523A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
WO2013025853A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
|
WO2013043864A1
(en)
*
|
2011-09-23 |
2013-03-28 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to endothelial targeting
|
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
|
CA2857114A1
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
EP2831115A1
(en)
|
2012-03-27 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Diagnosis and treatments relating to her3 inhibitors
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
WO2013192294A1
(en)
*
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
|
CN105050619A
(zh)
|
2012-12-03 |
2015-11-11 |
梅里马克制药公司 |
用于治疗her2-阳性癌症的组合疗法
|
|
US10519247B2
(en)
*
|
2013-11-01 |
2019-12-31 |
Board Of Regents,The University Of Texas System |
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
|
|
BR112016022910A2
(pt)
|
2014-04-11 |
2017-10-17 |
Medimmune Llc |
anticorpos contra her2 biespecíficos
|
|
TWI695011B
(zh)
*
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗ｈｅｒ２表位之單株抗體及其使用之方法
|
|
US20160045596A1
(en)
|
2014-08-05 |
2016-02-18 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
|
|
US10632180B2
(en)
|
2015-02-06 |
2020-04-28 |
The Regents Of The University Of California |
Methods and compositions for improved cognition
|
|
EP3514181A1
(en)
*
|
2015-02-24 |
2019-07-24 |
Academia Sinica |
A phage-displayed single-chain variable fragment library and antibodies selected therefrom
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
SG10201913073YA
(en)
|
2015-08-20 |
2020-03-30 |
Ipsen Biopharm Ltd |
Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
|
|
SG10201913077QA
(en)
|
2015-08-21 |
2020-02-27 |
Ipsen Biopharm Ltd |
Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
|
|
CN114073678A
(zh)
|
2015-10-16 |
2022-02-22 |
易普森生物制药有限公司 |
稳定喜树碱药物组合物
|
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
|
SG11201804839WA
(en)
|
2015-12-14 |
2018-07-30 |
Macrogenics Inc |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
|
BR112019007844A2
(pt)
|
2016-11-02 |
2019-07-16 |
Ipsen Biopharm Ltd |
tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
SG11202005557TA
(en)
|
2017-12-12 |
2020-07-29 |
Macrogenics Inc |
Bispecific cd 16-binding molecules and their use in the treatment of disease
|
|
CN111787949A
(zh)
|
2018-02-15 |
2020-10-16 |
宏观基因有限公司 |
变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
|
|
EP3920887B1
(en)
|
2019-02-04 |
2024-08-14 |
The Regents of the University of California |
A phosphatidylinositol-glycan-specific phospholipase d1 (gpld1) polypeptide for use in a method of treating or preventing age-related cognitive dysfunction
|
|
EP4103223A4
(en)
|
2020-02-12 |
2024-05-29 |
The Regents of the University of California |
PLATELET FACTORS AND COGNITIVE IMPROVEMENT
|
|
JP7745556B2
(ja)
|
2020-02-21 |
2025-09-29 |
マクロジェニクス，インコーポレーテッド |
Ｃｄ１３７結合分子及びその使用
|
|
CN116635064A
(zh)
|
2020-12-18 |
2023-08-22 |
世纪治疗股份有限公司 |
具有适应性受体特异性的嵌合抗原受体系统
|
|
US12428457B2
(en)
|
2021-01-29 |
2025-09-30 |
University Of South Florida |
Cold-shock protein scaffold for engineering non-antibody binding proteins
|
|
WO2024092238A1
(en)
|
2022-10-28 |
2024-05-02 |
Unity Biotechnology, Inc. |
Klotho polypeptide or polynucleotide for improving cognition
|
|
EP4414386A1
(en)
*
|
2023-02-09 |
2024-08-14 |
Mariangela Figini |
Method of chemical synthesis of single-chain antibody fragments and products thereby obtained
|